All News
New for HS
- Bimekizumab is 3rd FDA approved therapy based on BE HEARD 1&2
- Other approved ADA (2015, PIONEER 1&2), SEC (2023, SUNRISE/SUNSHINE)
Clinical trials:
IL23 failed, ILalpha failed
Brodulamab (IL17a) clinically meaningful response
TNF trials
@RheumNow #ACR2025 https://t.co/BfzwNQ1wUB
Links:
Eric Dein ericdeinmd ( View Tweet)
The ‘dark’ side of
#Hidradenitis #suppurativa
👇
Smell of leaking lesions #HS
⬆️skin folds, buttock, axilla, also thighs, neck
⬆️depression
@RheumNow #RNL2025
‘ If pt doesn’t get in gown then not ready for systemic #Rx!’
Jennifer Clay
#ClinicalPearl https://t.co/tZzz5tielt
Links:
Janet Pope Janetbirdope ( View Tweet)
Pregnancy is 🔥 inflammatory
Hard to interpret MRI of SI joints in setting of pregnancy
Ideally, don't score MRI during pregnancy or 1 year afterwards, would be affected by the pregnancy
If needed for clinical eval, focus on structural lesions like erosions
#RNL2025 @RheumNow
Eric Dein ericdeinmd ( View Tweet)
Combination therapy in PsA . Regulatory and reimbursement issues may inhibit such strategies (and potential adverse event concerns) but anecdotal evidence would suggest a role in difficult to treat cases. @RheumNow #RNL2025 https://t.co/IIoUiJyP95
Richard Conway RichardPAConway ( View Tweet)
Pearls on Dermatomyositis:
-Negative myomarker does not r/o DM
-Pruritus can be a skin manifestation in DM🚨
-Combination therapy upfront =achieve faster remission
-Evidence for JAK inhibitors in management
-JAKis seem to have good effect in DM-calcinosis
-In DM with rapidly… https://t.co/J3iiDa6ph7 https://t.co/0WTHKa97bt
Links:
Adela Castro AdelaCastro222 ( View Tweet)
Importance of not over-relying on lab tests. We can test for what we can test for, but this is not comprehensive. For me in clinical practice - Postive antibodies can confirm diagnosis of DM but negative cannot exclude it. @RheumNow #RNL2025 https://t.co/Kyfzne4BSD
Richard Conway RichardPAConway ( View Tweet)
Risk factors for development of PsA in psoriasis. Psoriasis severity, obesity, and depression. @alexisogdie @RheumNow @RNL2025 https://t.co/obMDBvLLnx
Richard Conway RichardPAConway ( View Tweet)
Can treatment of PsO prevent PsA?
-Severity of PsO and obesity->Risk fx for PsA
-PRESTO scores: Predicts whether you will develop PsA in the next year vs next 5 years
-Does ttx of PsO impact development of PsA?
Trials are mostly observational (several confounders)
TriNetX data:… https://t.co/TBv3Y2TLZv https://t.co/1K0MtMQ5gn
Links:
Adela Castro AdelaCastro222 ( View Tweet)
FDA has approved Journavx (suzetrigine) 50 mg tablets, 1st in-class non-opioid analgesic, to treat moderate to severe acute pain in adults. Journavx reduces pain by targeting a pain-signaling pathway involving sodium channels in the peripheral nervous system, before pain signals… https://t.co/qjtr4yz8Ot https://t.co/RUZmLgsmTv
Dr. John Cush RheumNow ( View Tweet)
Break a leg! Or a #hip
#AVN risk occurs even at 1 month of high / moderate dose #glucocorticoids
Shown by Michelle Petri @RheumNow #RNL2025
Risk in SLE is likely
👇
#disease #activity
And
#steroids
#SLE #systemic #lupus #erythematosus #steroids https://t.co/4EsQw9tY1u
Janet Pope Janetbirdope ( View Tweet)
Even a #SLE expert who wants all #lupus Pts on
No #chronic #prednisone
Realizes you can’t get everyone off #glucocorticoids
18% May be on chronic #steroids
But she keeps trying to taper
Michelle Petri
#RNL2025 @RheumNow https://t.co/SNP6Eep731
Janet Pope Janetbirdope ( View Tweet)
Predicting #PsA
PRESTO study #obvious risks are #predictive
Alexis R Ogdie @RheumNow #RNL2025
bad PsO 2X ^PsA
High BMI
Depression
Modifiable risks #psoriasis #psoriatic #arthritis https://t.co/pOxidCWcg5
Janet Pope Janetbirdope ( View Tweet)
Who’s liable for an incorrect #AI diagnosis or medical advice? @rheumnow #RNL2025 @RADoctor
TheDaoIndex KDAO2011 ( View Tweet)
Some pearls from RA POD at #RNL2025
-What do rheumatologists want from AI: Right drug for right patient, improving documenting in less time and possibly include multimorbidity management?
-Utilize AI as enhancer not replacement of the physician. AI must be trained well in a… https://t.co/9YNmeVx4t6
Adela Castro AdelaCastro222 ( View Tweet)
How can AI be useful for RA pts and rheumatologists?
-AI models have the potential for improving diagnosis, management and outcomes in RA pts.
-Can also improve efficiency and clinic workflow.
-Not so perfect as it sounds (hallucinations, limited accuracy)
#RNL2025 @RheumNow https://t.co/44LUHQ1KPf
Adela Castro AdelaCastro222 ( View Tweet)
Late onset RA (LORA) aka RA diagnosed at an older age — pts have higher inflammatory markers, presents like PMR; they also have polypharmacy, comorbidities, frailty, etc that can complicate management
@UnaMakris #RNL2025 @RheumNow #GeriRheum https://t.co/zqEcyg2ejw
TheDaoIndex KDAO2011 ( View Tweet)
Can #AI help us determine the
👇
Right drug
At
Right time
Pipe dream?
Or to use #artificial #intelligence term
➡️ a #hallucination?
garbage in ➡️➡️garbage out
Most predictions of drug response are same: multimorbid multiRx failures
Nonadherent poverty #RNL25 @RheumNow https://t.co/70SRp8BnCl
Janet Pope Janetbirdope ( View Tweet)
Such an important topic from @UnaMakris . The intersection of aging with our rheumatic disease processes is a crucial area. @RheumNow @RNL2025 https://t.co/n0Kx559g9e
Richard Conway RichardPAConway ( View Tweet)
Are your patients aging with RA, or are they diagnosed with Late Onset RA (LORA)?
-LORA pts tend to present acutely
-High inflammatory markers~PMR Like
-Seronegative/Decreased titers of RF/CCP
@UnaMakris
#RNL2025 @RheumNow https://t.co/aOCwb3lHef
Adela Castro AdelaCastro222 ( View Tweet)
Rituximab is FDA approved for treatment of moderate to severe pemphigus, but 20% may relapse in 1st Yr. Study of 87 pts shows the efficacy of repeat 6 mos RTX in A) those with persistent Dz activity and B) anyone w/ predictors of relapse (PDAI score, DSG1 or DSG3 abs)… https://t.co/IhqdGWVcdp https://t.co/MKhDpa5zHv
Dr. John Cush RheumNow ( View Tweet)
